EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) insider Gavin T. Jones purchased 50,000 shares of the stock in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average price of GBX 22 ($0.28) per share, for a total transaction of £11,000 ($14,237.64).
EKF Diagnostics Price Performance
Shares of EKF Diagnostics stock traded up GBX 0.70 ($0.01) on Friday, hitting GBX 21.90 ($0.28). The company's stock had a trading volume of 3,265,639 shares, compared to its average volume of 559,205. The company has a market capitalization of £97.34 million, a P/E ratio of 20.38 and a beta of 0.57. EKF Diagnostics Holdings plc has a 52-week low of GBX 18.40 ($0.24) and a 52-week high of GBX 33.80 ($0.44). The firm has a fifty day moving average price of GBX 23.04 and a 200-day moving average price of GBX 25.76. The company has a quick ratio of 1.77, a current ratio of 4.60 and a debt-to-equity ratio of 0.34.
EKF Diagnostics (LON:EKF - Get Free Report) last announced its quarterly earnings results on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share (EPS) for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. On average, equities research analysts expect that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.
About EKF Diagnostics
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Featured Stories
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
